哌嗪,1-(2-肼基乙基)-4-甲基盐酸 | 13562-46-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 哌嗪,1-(2-肼基乙基)-4-甲基盐酸
• 中文别名: 1-(2-肼基乙基)-4-甲基哌嗪盐酸盐
• 英文名称: 1-(2-hydrazino-ethyl)-4-methyl-piperazine
• 英文别名: 1-(2-Hydrazinylethyl)-4-methylpiperazine；2-(4-methylpiperazin-1-yl)ethylhydrazine
• CAS: 13562-46-4
• 化学式: C₇H₁₈N₄
• 分子量: 158.247
• InChiKey: YEOVCYPFIOCZIG-UHFFFAOYSA-N

物化性质

• 熔点：
  74-75℃

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  44.5
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2,4-二氯-N-(2,6-二氯l苯基)嘧啶-5-羧酰胺 、 哌嗪,1-(2-肼基乙基)-4-甲基盐酸 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 2-chloro-N-(2,6-dichlorophenyl)-4-(1-(2-(4-methylpiperazin-1-yl)ethyl)hydrazineyl)pyrimidine-5-carboxamide
  参考文献：
  名称：

  Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors

  摘要：

  A new series of pyrazolo[3,4-d]pyrimidine-3,6-diamines was designed and synthesized as potent and selective inhibitors of the nonreceptor tyrosine kinase, ACK1. These compounds arose from efforts to rigidify an earlier series of N-aryl pyrimidine-5-carboxamides. The synthesis and structure-activity relationships of this new series of inhibitors are reported. The most promising compounds were also profiled for their pharmacokinetic properties.

  DOI：

  10.1016/j.bmcl.2008.10.092

文献信息

• [EN] SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE NADPH OXYDASE
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2018203298A1

  公开（公告）日：2018-11-08

  The present application relates to substituted fused heteroaryl and heterocyclic compounds, useful as nicotinamide adenine dinucleotide phosphate oxidase inhibitors (NADPH oxidase inhibitors), processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by NADPH oxidase. (Formula I)

  本申请涉及取代的融合杂环芳基和杂环化合物，用作烟酰胺腺嘌呤二核苷酸磷酸酶抑制剂（NADPH氧化酶抑制剂），其制备方法，包含这些化合物的药物组合物，以及这些化合物或组合物在治疗或预防由NADPH氧化酶介导的各种疾病、症状和/或障碍中的用途。 (分子式I)
• Fused-ring heterocyclic compounds a process for their production and their pharmaceutical use
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0171217A2

  公开（公告）日：1986-02-12

  Fused ring compounds of formula (I): (where R1-R4, X1 and X2 represent hydrogen or various substituents, n and m are 1-3 and 2-7 respectively, the dotted lines are double or single bonds and Y is one oxygen or two hydrogens) have magnificent anti-arrhythmic activity, diuretic activity and the ability to improve brain function. For pharmaceutical use they may be formulated with carriers or diluents. They may be prepared by a ring-closing reaction of an indole derivative.

  式 (I) 的熔环化合物： (其中 R1-R4、X1 和 X2 代表氢或各种取代基，n 和 m 分别为 1-3 和 2-7，虚线为双键或单键，Y 为一个氧或两个氢）具有很强的抗心律失常活性、利尿活性和改善大脑功能的能力。用于制药时，它们可与载体或稀释剂一起配制。它们可以通过吲哚衍生物的闭环反应制备。
• QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
  申请人：Principia Biopharma Inc.

  公开号：EP3102577B1

  公开（公告）日：2018-07-18
• SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS
  申请人：Glenmark Pharmaceuticals S.A.

  公开号：EP3619209A1

  公开（公告）日：2020-03-11
• US4593027A
  申请人：——

  公开号：US4593027A

  公开（公告）日：1986-06-03